I concur. Also, back away from the hourly chart and look at the daily trajectory. As you can plainly see, Elite share price is moving upward. It's not an over-night pop like many would prefer; however, a gradual climb in price creates underlying support.
I'm guessing Pfizer or a major pharmaceutical competitor will move to buy the patent, seek exclusive licensure, or buyout Elite completely. Think about it. Pfizer is producing Oxecta on behalf of Acura pharma - currently the only competition for abuse-defeating drug delivery in an OxyContin product. They own this market. What would it be worth to Pfizer to see Elite's newest patent shelved or otherwise unavailable to other pharma competitors? My guess is we are sitting on something special with today's patent. JMO
Market Data 
Markets 
AI
